The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 27, 2021

Filed:

Apr. 19, 2018
Applicant:

Duke University, Durham, NC (US);

Inventors:

John H. Sampson, Durham, NC (US);

Duane A. Mitchell, Gainesville, FL (US);

Kristen A. Batich, Durham, NC (US);

Michael D. Gunn, Durham, NC (US);

Assignee:

Duke University, Durham, NC (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/08 (2006.01); A61K 39/39 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 39/05 (2006.01); A61K 39/09 (2006.01); A61K 39/102 (2006.01); A61K 39/12 (2006.01); A61K 49/00 (2006.01); A61K 49/06 (2006.01); C07K 14/285 (2006.01); C07K 14/315 (2006.01); C07K 14/33 (2006.01); C07K 14/34 (2006.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/08 (2013.01); A61K 38/195 (2013.01); A61K 39/0011 (2013.01); A61K 39/05 (2013.01); A61K 39/092 (2013.01); A61K 39/102 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 49/0008 (2013.01); A61K 49/06 (2013.01); C07K 14/285 (2013.01); C07K 14/3156 (2013.01); C07K 14/33 (2013.01); C07K 14/34 (2013.01); C07K 14/4748 (2013.01); C07K 14/523 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/58 (2013.01); A61K 2039/585 (2013.01); A61K 2039/70 (2013.01); C07K 2319/55 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16171 (2013.01);
Abstract

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.


Find Patent Forward Citations

Loading…